MDAT

MDAT
Clinical data
Other names	6,7-MDAT; 6,7-Methylenedioxy-2-aminotetralin
Drug class	Serotonin releasing agent; Entactogen
ATC code	None;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-6-amine;
CAS Number	101625-35-8 ; hydrochloride: 3446-21-8 ;
PubChem CID	36483;
ChemSpider	33531;
UNII	28IR5LC41Q; hydrochloride: BOX4U52EET ;
CompTox Dashboard (EPA)	DTXSID501017047 ;
Chemical and physical data
Formula	C11H13NO2
Molar mass	191.230 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C3Cc1cc2OCOc2cc1CC3N;

MDAT, also known as 6,7-methylenedioxy-2-aminotetralin, is a drug of the 2-aminotetralin family developed in the 1990s by a team at Purdue University led by David E. Nichols. It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity. Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.